Andreas Halvorsen
Investment Philosophy
Andreas Halvorsen is the co-founder and CEO of Viking Global Investors, one of the most consistently successful hedge funds of the past two decades. A Norwegian by birth, Halvorsen studied at Williams College and served as a Navy SEAL before earning his MBA at Stanford — a background that instilled the discipline, rigorous risk management, and team cohesion that define Viking’s culture. He began his career at Tiger Management under Julian Robertson, where he developed the fundamental analytical framework that became the foundation of Viking’s edge.
Viking’s investment philosophy centers on deep fundamental research applied to a diversified long/short book. Unlike many Tiger Cubs who migrated toward concentrated long-only strategies, Halvorsen preserved the short-selling discipline — Viking actively generates alpha on both sides of the market. This requires a deeper analytical infrastructure: every position must have a clear thesis for why the stock will outperform or underperform on a 12–18 month horizon, supported by proprietary channel checks, management access, and exhaustive competitive analysis.
Halvorsen is known for rigorous position sizing discipline. Viking does not allow any single position to dominate the portfolio regardless of conviction level — the framework is built around managing aggregate factor exposures rather than individual security bets. This means Viking’s returns come more from the breadth of accurate calls than from a handful of concentrated wins. It is an institutional approach that prioritizes consistency of alpha generation over headline-grabbing returns in any single year.
Geographically, Viking’s long book is predominantly US-focused but with deliberate global diversification into European and Asian equities where Viking’s research team identifies structural mispricings. Halvorsen has cultivated a culture of intellectual honesty — Viking holds formal “devil’s advocate” sessions for large positions, where analysts are required to present the strongest case against the fund’s existing thesis. This institutionalized skepticism is a key reason Viking has avoided the catastrophic blow-ups that have ended other prominent funds.
Q4 2025 · Portfolio Moves & Analysis
In Q4 2025, Viking maintained Amazon as its largest long position — a conviction call on the convergence of AWS’s AI infrastructure dominance and Amazon’s retail margin expansion story. Halvorsen sees Amazon as a multi-decade compounding machine with three independent growth engines: cloud computing (AWS), advertising, and the ongoing margin expansion of the core retail business as fulfillment automation and third-party logistics mature. The position reflects confidence that the market still undervalues AWS’s AI tailwind.
Viking also maintained significant exposure to UnitedHealth Group and Eli Lilly — representing Halvorsen’s structural thesis on healthcare as a defensive growth sector. Lilly in particular is central to Viking’s view on the GLP-1 weight-loss drug revolution: Halvorsen believes the addressable market for Ozempic-class drugs has been systematically underestimated by sell-side analysts, and that Lilly’s manufacturing scale advantage will create a durable competitive position over the next 5–7 years.
The Q4 filing shows Viking adding selectively to financial sector positions, particularly in payment networks and financial technology. This reflects Halvorsen’s view that the AI-driven productivity gains in financial services are still in the very early stages — and that the companies building the infrastructure for AI-powered financial analysis will compound at rates the market is not yet pricing.
Current Portfolio
Source: SEC 13F Filing (Q4 2025)
| Ticker / Security Name | Shares | Δ Shares (%) | Value (Full $) | Portfolio (%) |
|---|---|---|---|---|
| MSFT / Microsoft Corp | 3.22M | +32.4% | $1,560,000,000 | 4.13% |
| PNC / Pnc Finl Svcs Group Inc | 7.29M | -8.4% | $1,520,000,000 | 4.04% |
| TSM / Taiwan Semiconductor Mfg Ltd | 4.91M | +24.6% | $1,490,000,000 | 3.96% |
| V / Visa Inc | 3.98M | +0.0% | $1,400,000,000 | 3.71% |
| SCHW / Schwab Charles Corp | 13.87M | -16.3% | $1,390,000,000 | 3.68% |
| DIS / Disney Walt Co | 11.19M | +7.1% | $1,270,000,000 | 3.38% |
| APD / Air Prods & Chems Inc | 4.78M | +30.4% | $1,180,000,000 | 3.14% |
| MCD / Mcdonalds Corp | 3.62M | +7.2% | $1,110,000,000 | 2.94% |
| BBIO / Bridgebio Pharma Inc | 14.39M | -9.9% | $1,100,000,000 | 2.92% |
| FTV / Fortive Corp | 19.23M | -6.1% | $1,060,000,000 | 2.82% |
| SHW / Sherwin Williams Co | 3.17M | +10.1% | $1,030,000,000 | 2.73% |
| BA / Boeing Co | 3.95M | -60.9% | $858,300,000 | 2.28% |
| GOOGL / Alphabet Inc | 2.67M | New | $834,500,000 | 2.21% |
| AMD / Advanced Micro Devices Inc | 3.74M | +23.9% | $801,400,000 | 2.13% |
| ICE / Intercontinental Exchange In | 4.80M | -10.5% | $777,900,000 | 2.06% |
| TSLA / Tesla Inc | 1.70M | +5.6% | $764,400,000 | 2.03% |
| TMUS / T-mobile Us Inc | 3.75M | +15.1% | $762,300,000 | 2.02% |
| AMZN / Amazon Com Inc | 3.13M | -51.7% | $721,700,000 | 1.92% |
| Capital One Finl Corp | 2.95M | -60.0% | $715,500,000 | 1.90% |
| Johnson Ctls Intl Plc | 5.92M | -12.9% | $708,800,000 | 1.88% |
| Draftkings Inc New | 19.12M | +27.4% | $658,900,000 | 1.75% |
| JPM / Jpmorgan Chase & Co. | 1.91M | -62.3% | $614,100,000 | 1.63% |
| Ross Stores Inc | 3.17M | +56.5% | $570,600,000 | 1.51% |
| General Mtrs Co | 6.81M | -47.8% | $553,500,000 | 1.47% |
| Mid-amer Apt Cmntys Inc | 3.88M | +46.7% | $539,000,000 | 1.43% |
Outlook 2026 · What to Watch
For Viking in 2026, the key watchpoints center on three themes: First, Amazon’s AWS growth acceleration. The critical inflection will be whether AWS’s revenue growth rate re-accelerates above 20% as AI workloads drive incremental cloud spend. Halvorsen’s Amazon thesis depends on this acceleration — if AWS growth stagnates, the valuation multiple becomes harder to justify. Q1 2026 earnings will be the first major data point.
Second, Eli Lilly’s manufacturing capacity ramp. The GLP-1 opportunity is constrained by supply, not demand — Lilly’s ability to scale manufacturing of Zepbound and tirzepatide will determine 2026 revenue. Viking’s position is essentially a bet that Lilly executes on its manufacturing expansion program, which would allow the company to meet the enormous unmet demand that currently exceeds supply by a factor of 3–5x.
Third: watch Viking’s short book for signals. While 13F filings only reveal long positions, Halvorsen’s short-side activity often mirrors macro themes he is expressing directionally. Sectors with heavy sell-side consensus bullishness — overvalued AI application companies with no clear monetization path, legacy enterprise software facing AI disruption — are likely short targets for Viking’s research team in 2026.
This is BMInsider PRO Content
You are reading a deep analysis — our most detailed research.
Unlock full access to all analyses, Smart Money insights & more.
Unlock BMInsider PRO →